TOO STRINGENT PATIENT SELECTION CRITERIA IN A CLINICAL-TRIAL OF ALPHA-BLOCKERS REDUCE THE VALUE OF THE RESULTS

被引：0
|
作者：
ROSENBAUM, TP
SHAW, PJR
机构：
来源：
EUROPEAN UROLOGY | 1991年 / 20卷 / 03期
关键词：
ALPHA-BLOCKERS; PROSTATISM; CLINICAL TRIALS;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The patient selection criteria in a clinical trial of an alpha-blocker for the treatment of benign prostatic hypertrophy were such that 85% of the patients on the waiting lists of 4 hospitals had to be excluded. The value of such a trial is discussed. Trial protocols should be designed to allow the enrolment of patients truly representative of the patients for which the treatment is intended.
引用
收藏
页码：175 / 178
页数：4
相关论文
共 29 条
  • [21] Clinical-biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and provide hypotheses for patient selection criteria for further clinical trials
    Klisovic, Rebecca B.
    Coutre, Steven
    Kovacsovics, Tibor J.
    Kantarjiam, Hagop M.
    Tricot, Guido J.
    Strovel, Jeffrey W.
    Genna, Thomas
    Bol, David K.
    Hamilton, Michael
    Mitchell, Beverly S.
    BLOOD, 2007, 110 (11) : 273A - 274A
  • [22] Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort
    Coates, Laura C.
    Tillett, William
    Shaddick, Gavin
    Pincus, Theodore
    Kavanaugh, Arthur
    Helliwell, Philip S.
    ARTHRITIS CARE & RESEARCH, 2018, 70 (08) : 1198 - 1205
  • [23] TREATMENT OF RECURRENT MALIGNANT GLIOMA BY REPEATED INTRACEREBRAL INJECTIONS OF HUMAN RECOMBINANT INTERLEUKIN-2 ALONE OR IN COMBINATION WITH SYSTEMIC INTERFERON-ALPHA - RESULTS OF A PHASE-I CLINICAL-TRIAL
    MERCHANT, RE
    MCVICAR, DW
    MERCHANT, LH
    YOUNG, HF
    JOURNAL OF NEURO-ONCOLOGY, 1992, 12 (01) : 75 - 83
  • [24] Determinants of quality of life in atrial fibrillation and the clinical value of measurement: focus group results: from the RATE-AF trial led by a patient & public involvement team
    Jones, Jacqueline
    Stanbury, Mary
    Mathers, Jonathan
    Calvert, Melanie
    Kotecha, Dipak
    QUALITY OF LIFE RESEARCH, 2018, 27 : S51 - S51
  • [25] The additional value of a home physical therapy regimen versus patient education only for the treatment of myofascial pain of the jaw muscles: Short-term results of a randomized clinical trial
    Michelotti, A
    Steenks, MH
    Farella, M
    Parisini, F
    Cimino, R
    Martina, R
    JOURNAL OF OROFACIAL PAIN, 2004, 18 (02): : 114 - 125
  • [26] Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
    Walsh, Jessica
    Coates, Laura
    Mease, Philip J.
    Merola, Joseph
    Nash, Peter
    Ogdie, Alexis
    Tillett, William
    Gisondi, Paolo
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Lambert, Jeremy
    Taieb, Vanessa
    Willems, Damon
    Erik, Lars
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4194 - 4196
  • [27] Swollen and tender joint counts are rated of highest value and patient functional status and erythrocyte sedimentation rate (ESR) of lowest value by 363 US rheumatologists to assess results of clinical trials in patients with rheumatoid arthritis (RA), but clinical trial data indicate that placebo improvement is highest for joint counts and lowest for patient functional status and ESR.
    Pincus, T
    Wolfe, F
    Cohen, SB
    Strand, V
    Simon, L
    Tugwell, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S400 - S400
  • [28] RAPID3 (Routine Assessment of Patient Index Data 3) Severity Categories and Response Criteria: Similar Results to DA528 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) Clinical Trial of Certolizumab Pegol
    Pincus, Theodore
    Furer, Victoria
    Keystone, Edward
    Yazici, Yusuf
    Bergman, Martin J.
    Luijtens, Kristel
    ARTHRITIS CARE & RESEARCH, 2011, 63 (08) : 1142 - 1149
  • [29] Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection
    Provencio, Mariano
    Majem, Margarita
    Guirado, Maria
    Massuti, Bartomeu
    de Las Penas, Ramon
    Laura Ortega, Ana
    Domine, Manuel
    Marse, Raquel
    Angeles Sala, Maria
    Paredes, Alfredo
    Moran, Teresa
    Vazquez, Sergio
    Coves, Juan
    Gonzalez Larriba, Jose Luis
    Miguel Sanchez, Jose
    Vicente, David
    Farre, Nuria
    Fernandez Fornos, Luis
    Zapata, Irma
    Franco, Fabio
    Serna-Blasco, Roberto
    Romero, Atocha
    Isla, Dolores
    LUNG CANCER, 2021, 153 : 25 - 34
123